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Microtubule poisons have proven to be effective in the treatment of a variety of 
malignancies.  Although taxol-based derivatives promote microtubule stabilization, there is 
continuing interest in compounds that, like colchicines, act as microtubule destabilizing 
agents.  Previous work from this laboratory showed that the novel microtubule poison, JG-
03-14, was active against breast tumor cells, promoting autophagic cell death.  In the 
current work, we studied the influence of JG-03-14 on p53 wild type HCT116 colon 
carcinoma cells.  A crystal violet sensitivity assay indicated that JG-03-14 induced growth 
9 
inhibition, with 75% suppression of growth evident at a concentration of 500 nM.  Time 
course studies of drug effects on cell viability indicated that JG-03-14 also produced cell 
killing. FACS analysis demonstrated that the HCT-116 cells arrested in the G2/M stage; 
furthermore, there was evidence of a hyperdiploid population that would be consistent with 
failure of the cells to divide despite completion of DNA synthesis. Finally, there was 
evidence of a small sub G0/G1cell population, indicating that the cells were not dying 
primarily by apoptosis, and suggesting that JG-03-14 induces an alternative mode of cell 
death.  In contrast to cell shrinkage and nuclear fragmentation that was evident after 
treatment with taxol ( a positive control for apoptosis), DAPI staining of HCT-116 cells 
treated with JG-03-14 showed intact and enlarged nuclei, again consistent with the absence 
of apoptosis. Furthermore, there was no evidence of mitotic catastrophe (micronuclei in 
binucleated cells).  Based on previous studies in MCF-7 and MDA-MB231 cell lines that 
demonstrated a substantial population of autophagic cells, HCT-116 cells were subjected 
to staining with acridine orange and monodansylcadaverine after treatment with JG-03-14. 
While control cells tended to show a single large autophagic vesicle closely associated 
with the cell nucleus, treatment with JG-03-14 resulted in extensive distribution of small 
acidic vesicles within the cytoplasm, indicative of autophagy. GFP-LC3 transfected cells 
incubated with JG-03-14 showed punctuated patterns that were also consistent with the 
promotion of autophagy. Finally, activation of the DNA damage response pathway was 
ruled out by the lack of induction of p53 and p21 in cells treated with JG-03-14.  In 
summary, our studies indicate that the JG-03-14 induces both growth arrest and autophagic 
cell death in HCT116 colon carcinoma cells.  The possibility of an alternative mode of cell 
10 
death induced by JG-03-14 makes it a potentially usefull candidate as a chemotherapeutic 
drug that could be used to treat cancers resistant to apoptosis.  Our result also suggested 
that JG-03-14 failed to induce bone marrow toxicity adding to its potential for clinical use.  
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CHAPTER 1 Introduction 
 
I. Colon Cancer 
In the US, cancer accounts for one in every four deaths, with colorectal 
cancer as the second leading cause of cancer death (American Cancer Society, 
2008).  Death from colorectal cancer is attributed to the metastatic form of the 
disease rather than the primary tumor (Delaunoit et al, 2005).  Drug resistance 
accounts for greater than 90% of treatment failure in patients with metastatic 
disease, with colon cancer being completely refractory to currently approved 
microtubule targeting agents, such as taxanes (Fojo et al, 2007; Sampath et al, 
2006).  The use of chemotherapy in the treatment of colon cancer would be 
facilitated by the development of chemotherapeutic agents that have high potency, 
efficacy in destroying the tumor cells, selectivity for the tumor target versus normal 
host cells and refractory to the common resistance mechanisms in colon cancer.    
 
 II. Anti-tubulin compound for chemotherapy 
Microtubules are crucial to cellular metabolism, intracellular transport, and 
cell division (Nogales, 2001).  A variety of natural compounds and their derivatives 
have been shown to disrupt microtubule function (Xiao et al, 2005).  These 
compounds fall into two categories: microtubule stabilizers (polymerization) or 
microtubule  destabilizers (depolymerization); the latter group can be further 
subdivided into those compounds that bind to the colchicine binding site of tubulin 
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or the vinca alkaloid binding domain (Kuo et al, 2004).  The microtubule stabilizers 
such as paclitaxel (taxol), discodermolide, and epothilones stimulate the assembly 
of purified tubulin whereas the destabilizers disrupt the assembly of purified 
tubulin.   Combretastatin A-4, podophyllotoxin and 2-methoxyestradiol (2ME2) are 
microtubule destabilizers that bind to the colchicine binding site.  Drugs that inhibit 
microtubule dynamics can ultimately hinder normal mitotic spindle function, 
leading to mitotic arrest and initiation of apoptosis or autophagy (Pasquier et al, 
2008; Arthur et al, 2007).   
 
 III. Response to drug treatment 
 A. Apoptosis 
Apoptosis is a form of programmed cell death that includes the extrinsic 
pathway, which is activated by proapoptotic receptors at the cell surface and/or the 
intrinsic pathway, which is activated by mitochondrial signals, where both 
pathways converge on the executioner caspase, caspase 3, that signals to 
effectors leading to cell death (Song et al, 2008; Wang et al, 2008; Ashkenazi and 
Herbst 2008).  In addition, apoptosis has also been shown to occur via a caspase-
independent mechanism (Cummings et al, 2004).  Apoptosis is characterized by 
membrane blebbing that pinches off into small apoptotic bodies, condensation and 
fragmentation of the nucleus and DNA (Taylor et al, 2008).  Activation of apoptosis 
can occur via the DNA damage response protein p53 or by a p53 independent 
mechanism (Gulbins et al, 2000).  Resistance to chemotherapy that is associated 
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with the p53 dependent induction of apoptosis is often related to mutations in p53 
and evasion of the p53 signaling pathway (Chendil et al, 2000). 
 B. Autophagy 
Autophagy is characterized by the sequestration of proteins and organelles 
into a double membrane acidic vesicle that eventually becomes degraded (Figure 
C) (Gozuacik and Kimchi, 2004).   The process begins with a double membrane 
that enwraps around a portion of the cytosol, containing organelles and proteins, 
to form the autophagosomes.  The autophagosome then fuses with the lysosome, 
forming an autolysosome, where the contents are degraded.  This process is 
conserved from yeast to human but differs in the site of induction, with pre-
autophagosomal structures (PAS) next to the vacuole in yeast but with multiple 
sites in mammalian cells (Jahreiss et al. 2008; Qadir et al, 2007).   There are three 
types of autophagy, microautophagy, macroautophagy, and chaperone-mediated 
autophagy, but these will not be distinguished  for the purpose of this study.  It has 
been shown that autophagy can be activated by the PI3K-Akt-mTor pathway, 
nutrient deprivation, ceramide, and Atg proteins (Lavieu et al, 2007; Mizushima et 
al, 2008).  Chemotherapeutics drugs have also been shown to promote autophagy 
in tumor cells (Cui et al, 2007).   
The process of autophagy under nutrient deprivation is under the control of 
the PI3-K-Akt-mTor pathway (Ravikumar et al, 2004).  When nutrients are 
abundant, the mTor pathway is activated and inhibits autophagy; however, under 
conditions of nutrient depletion, mTor becomes inactivated and autophagy is no 
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longer suppressed.  Though the process of autophagy by nutrient deprivation is 
well characterized, the role of autophagy in response to chemotherapeutic drugs 
requires extensive investigation.        
A widely used method for detection of autophagy is to monitor the levels of 
autophagy associated proteins .  The yeast Atg8 homologue MAP-light chain 
3(LC3) appears to have a crucial role in the expansion and completion of 
autophagosome formation (Kouno 2005; Kabeya et al. 2000).  MAP-LC3 is 
cleaved by a cysteine protease Atg4 and activated by Atg7 to produce LC3-I, 
found in the cytosol (Sou et al. 2006).  After its generation, LC3-I is converted to 
LC3-II via the actions of E1 and E2 (both are ubiquitin like proteins, Atg7 and Atg3 
respectively) and locates to the autophagic membrane.  The target of LC3-II has 
been identified to be phosphatidylethanolamine (PE), found on the 
autophagosome membrane.  This tight binding between LC3-II and PE is thought 
to promote autophagosome maturation and then fusion of the autophagosome 
with the lysosome to complete autophagy (Asanuma et al, 2003; Sou et al, 2006; 
Tanida et al, 2002). 
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Figure C – Autophagy pathway 
 
IV. Drug Resistance   
The clinical success of cancer chemotherapy is often limited by the 
challenge of resistance to antitumor drugs by cancer cells.   Some relatively 
frequent mechanism of resistance includes decreased drug accumulation in tumor 
cells, drug inactivation in tumor cells, increased DNA repair, and amplification or 
mutation of drug target genes (Eastman and Schulte, 1988; Lai et al, 1988; Cazin 
et al, 1992).  Some of the enzymes responsible for drug inactivation includes 
glutathione S-transferase and aldehyde dehydrogenase (Hoban et al, 1992; Hilton, 
1984)  Drug resistance pumps are often responsible for the decrease in drug 
accumulation in cancer cells and can involve p-glycoprotein, a membrane pump 
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that can extrude a wide range of antitumor drugs, as well as other multidrug 
resistant protein pumps  (Harris et al, 1992;  Baines et al, 1992; Lizano et al, 1993 
.) Chemotherapeutic drug resistance is a cause of frequent treatment failure in 
colon cancer (Fojo et al, 1987; Hengstler et al, 1998).  Resistance to drugs that 
are widely used in the treatment of colon cancer such as the antimetabolite 5-
fluorouracil, the topoisomerase I inhibitor irinotecan, and the DNA damaging 
agent, oxaliplatin, have been reported (Boyer et al, 2004; Oliver et al, 2002).  Loss 
of response to apoptosis mediated cell death can often be attributed to a defect in 
p53 status (Violette et al, 2002).  As a result, drug development requires the 
identification of compounds that are poor substrates for the multidrug efflux 
pumps.  In addition, drug combination treatments represent a strategy to evade 
the intrinsic drug resistance mechanisms of tumor cells (Hiro et al, 2008).   
 
 V.  Substituted pyrroles as anti-tumor drugs  
Pyrroles are components of a more complex macrocycle that is made up of 
a substituted aromatic ring structure Figure A.  They are components of the 
complex macrocycles such as porphyrin of heme and the chlorines and 
bacteriochlorins of chlorophyll (Katsiaouni et al, 2008; Wu et al, 1985).  Pyrrole 
compounds such as CC-1065, distamycin and duocarmycins are a natural class of 
antibiotics that have antitumor activities (Shinohara et al, 2006; Nagamura et al, 
1996; Hiraku et al, 2002).  Prompted by the readily available natural material and 
the ability to make major or minor alterations to the natural structure has led 
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researchers to screen for more natural products.  Lamellarins are another class of 
pyrroles that have been obtained from a natural source, the marine prosobranch 
mollusk, and which have been shown to have antitumor activity as well as the 
capacity to reverse multidrug resistance (Quesada et al, 1996; Davis et al, 1999).  
It was observed that lamellarins along with many marine derived pyrroles possess 
a 3,4-diarylated pyrrole 2-carboxylic acid ester or amide moiety (Fan et al, 2007).   
The oxygenated 3,4-diaryl substitution appears to be associated with the MDR 
reversal behavior while the phenolic hydroxyl groups are associated with the 
cytotoxic behavior (Gupton 2006). 
 
Figure A – Structure of a pyrrole 
 
The discovery of drug templates derived from natural sources, where 
modifications to maximize pharmacokinetics and pharmacodynamic properties of 
the compound are easily performed, has led to the generation of versatile 
synthetic analogs.  
A recent class of substituted pyrrole compounds is based on a 3,4-
diarylated pyrrole 2-carboxylic acid ester Figure B.   Out of the group of 
brominated pyrroles, JG-03-14 has been shown to bind at the colchicine binding 
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site of tubulin between the alpha and beta interfaces on purified tubulin  (Mooberry 
et al, 2007).  Studies have indicated that JG-03-14 is cytotoxic at a concentration 
of  500nM and it has been demonstrated to initiate both apoptosis and autophagy 
in MCF-7 and MDA-MB-231 breast tumor cells (Arthur et al, 2007).  While some 
studies in the literature suggest that functional p53 is required for autophagy 
(Abida and Gu, 2008) JG-03-14 also induced autophagy in p53 mutant MDA-MB-
231 breast cancer cells. The mechanisms by which JG-03-14 induces autophagy 
in MCF-7 and MDA-MB-231 breast cancer cells and the role of functional p53 
requires further elucidation.   
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Figure B- Strucutres of the substituted pyrroles.  JG-03-14 is used in this 
study. 
 
The aim of our study was to determine if JG-03-14 might also have antiproliferative 
and or cytotoxic effects in HCT116 colon carcinoma cells, the mode(s) of cell 
death is induced by JG-03-14, and whether the compound activates p53 proteins 
and/or p21Waf1/Cip1.   
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CHAPTER 2 Materials and Methods 
 
Cell Culture 
HCT116 p53 wild type colon carcinoma cells were obtained from ATCC and 
kept frozen in 10% DMSO (Sigma Chemical, St. Louis, MO) with Fetal Bovine 
Serum (FBS)(GIBCO Life Technologies, Gaithersburg, MD) until use.  Cells were 
quickly thawed and cultured in a T75 flask (Cellstar) in basal RPMI 1640 medium 
supplemented with 5% fetal bovine serum, 5% bovine calf serum, 2 mM L-
glutamine, and penicillin/streptomycin 0.5 ml/100 ml medium(10,000units/ml 
penicillin and 10 mg/ml streptomycin; GIBCO Life Technologies, Gaithersburg, 
MD) at 370 C under a humidified, 5% CO2 atmosphere.  Cells were passaged at 
80% confluency by washing one time with 1X PBS(GIBCO), harvested with 
trypsin-EDTA 0.25 %(GIBCO) and then deactivated with RPMI medium, collected 
and centrifuged at 15,000 rpm for 3 minutes.  Media was aspirated and fresh 
media was added to the cell pellet; cells were re-suspended in media and 300 µl of 
the cell resuspension was placed into a fresh T75 flask with 10mL RPMI medium.  
For all culture experiments, cells were plated and permitted to adhere overnight 
before drug treatment.  All treatment involved continuous drug exposure.     
 
 
 
21 
MTT assay 
Cells were prepared as described above.   Using a 96 well plate, 5,000 
cells/150uL media were plated per well and allowed to adhere overnight before 
drug treatment.  After 72 hours, 100 µl of the MTT solution ( 2mg/mL PBS 
prepared in the dark) was added to each well and incubated for 3 hours at 370 C 
The MTT solution was removed and 100µl  of DMSO was added to each well, and 
the blue dye was allowed to dissolve for 5 minutes.  An absorbance reading was 
taken at 490 nm (KC Junior software, EL800 Universal Microplate Reader).  
 
Crystal Violet Assay 
Cells were prepared as described above. The crystal violet assay, as 
described by Wosikowski et al, (1993), was used to determine drug effects on cell 
viability.  In a 48 well plate, 20,000 cells /500 µl  media were plated per well and 
allowed to adhere overnight.  After 72 hours of treatment, the drug was aspirated 
and the cell monolayer was fixed with 100% methanol for 10 minutes. The 
methanol was aspirated and a crystal violet 0.5% solution in 25% methanol was 
used to stain the cells for 10 minutes.  The stain was removed and cells were 
washed 4 times to remove excess dye.  Fixed cells were left to air dry overnight.  
The next day, cells were solubilized in 1 ml 0.1 M sodium citrate in 50% ethanol 
and placed on a shaker for 10 minutes.  Absorbance readings were taken at 
540nm. 
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Time Course of Drug Effects on Viable Cell Number 
Cells were prepared as described above.  Cells were plated at 1X10^6 cells per 96 
mm Petri plate (CellStar) and allowed to adhere overnight.  At the various time 
points, media containing the drug was aspirated and cells were washed once 
using 1X PBS.  Cells were then harvested and centrifuged at 15,000 rpm for 3 
minutes and media was removed.  The cell pellet was resuspended in fresh media 
and 10µl  of the cell resuspension was added to 90µl  of 0.4% trypan blue 
exclusion dye (1:9; trypan blue: PBS).  10µl of the mixture was placed onto a 
hemocytometer and viable cells (those that excluded the dye) were counted using 
the phase contrast microscopy.   
 
DAPI Staining for Apoptosis and Mitotic Catastrophe 
Cells were prepared and treated as in the time course studies, above.  The 
assay used was from Gavrieli et al, 1992.  At the various time points, adherent and 
non-adherent cells were harvested and  centrifuged at 15,000 rpm for 3 minutes.  
The media was aspirated and fresh media was added to resuspend the pellet.  
Viable cell numbers was determined using trypan blue exclusion dye as described 
previously.  A dilution of 20,000 cells in 200 µl  of 1X PBS per slide was prepared 
and cells were spun at 10,000 rpm for 5 minutes (Shandon Cytospin 4, Thermal 
Electron Corp). Slides were refrigerated until ready for staining.  Cells were fixed 
with 4% formaldehyde in PBS for 10 minutes at room temperature, and then  
washed with PBS twice for 5 minutes at room temperature.  A 1:2 dilution of acetic 
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acid and ethanol was used to fix the cells at 200 C for 5 minutes.  The slides were 
then washed twice with PBS for 5 minutes at room temperature.  A 1:1000 dilution 
was prepared for Vectashield :Dapi and each slide was mounted with 10µl  of the 
solution.  Coverslips were sealed using clear nail polish and photographs were 
taken at 10X using a Nikon fluorescent microscope and an Olympus camera.  
Slides were stored at 4 0 C , and three field per condition were evaluated.   
 
Flow Cytometry  
Cells were plated at 3 million cells per 96 mm Petri plates for each time 
point and allowed to adhere overnight.  Setup was prepared for day 5 and worked 
backward so that all treatments would complete on the same date.  Drug treatment 
was initiated the following day and drug was left on the cells for continuous 
exposure.  Upon the completion of treatment, media was aspirated and cells were 
washed one time with 1X PBS.  Cells were harvested using trypsin and 
deactivated with 10ml media, then centrifuged at 15,000 rpm for 3 minutes.  Media 
was aspirated and the cell pellet was resuspended in fresh media.  Viable cell 
number was determined by trypan blue exclusion dye.  At least 1 million cells per 
condition were used in the cell cycle analysis.  1.5 ml of Propidium iodide stain 
with RNAse was added to each million cells.  The cell suspension was filtered 
through a 70 micron mesh 2 times.  All samples were covered in aluminum foil and 
refrigerated until the next day.   FACs acquisition was performed using the EPICS 
753 flow cytometer (Coulter Electronics, Hialeah, FL) using a 488 nm argon laser 
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and standard optical emission filters.  A minimum of 13,000 events were collected 
per sample.  Cellular DNA distributions were analyzed at the various stages of the 
cell cycle using Cytologic Software (Coulter Electronics). 
 
Acridine Orange staining for autophagy 
As a marker for autophagy, the acridine orange staining method described 
by Paglin et al, (2001) was used.  Cells were plated at 2 X 10^5 per 6 well plate 
and allowed to adhere overnight.  Drug was added the following day and left on for 
continuous exposure.  At the final time point, the drug was removed and cells were 
washed one time with 1X PBS.  Cells were then stained with acridine orange 
(1ug/ml) for 15 minutes.  .    
 
Monodansylcadaverine 
Monodansylcadaverine(MDC) is another marker for autophagy that stains 
the autophagic membrane (Niemann et al, 2000).  Cells were treated as described 
above.  MDC(Sigma) was dissolved in DMSO for a stock concentration of 100 
mM.  At selected time points, cells were stained with 0.5 mM 
monodansylcadaverine for 10 minutes.  The stain was removed and cells were 
washed with 1X PBS four times before fresh media was added to the wells.  
Pictures were taken with the inverted Nikon fluorescent microscope and an 
Olympus camera at 20X magnification 
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Transfection with GFP-LC3 
As a marker for autophagy, LC3 tagged GFP was used to detect the 
processing of the LC3 proteins in the autophagosomes (Kabeya et al, 2000).  Cells 
were prepared from frozen stock and passaged twice at least 2 days before 
nucleofection.  1 X 10^6 cells were centrifuged and suspended in a pellet.  100 µl 
of the Nucleofector V (Nucleofector Kit V, Amaxa) mix was added to resuspend 
the cells.  The resuspension was added to 1 µg of the GFP-LC3 vector and the 
entire suspension was transferred to the cuvette.  The cuvette was placed in the 
Nucleofector device and program D-032 was used to transfect the cells.  500 µl 
warm medium was added to the transfected solution and the total suspension was 
transferred to a Petri plate.  These steps were repeated for the positive and 
negative controls using 2 µg of empty vector-GFP, and 2 µg pmax-GFP. 
 
Western Blotting 
After the indicated times, cellular proteins were extracted from treated cells 
using 100 to 200 µL of 1X tris lysis buffer (1 M Tris(pH 6.8), 10% SDS, and dH2O) 
containing protease inhibitors with boiling for 5 minutes.  Protein concentration 
was determined with a Lowry protein assay and 10 µg of total cell lysates were 
separated using 12% SDS-PAGE.  Proteins were transferred onto nitrocellulose 
membrane for 1 hour and blocked in TBS-Tween 20 buffer containing 5% nonfat 
dry milk.  Membranes were then immunoblotted with the respective primary 
antibodies overnight in 200 C.  The following day, the membrane was incubated 
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with horseradish peroxidase-conjugated secondary antibody for 1 hour.  Signals 
were detected using an enhanced chemilluminescence detection reagents from 
Pierce (Rockford, IL).   
 
Assessing Bone Marrow Toxicity 
Two C57BL6 mice were sacrificed by cervical-cranial dislocation.  The 
femur and tibia of both mice were removed and all exo-skeletal parts were 
removed.  All muscle tissue was scraped off with a scalpel and bones were placed 
in 1X PBS.  The femur was cut at both ends to expose the hollow bone and fresh 
1X PBS was used to wash out the bone marrow cells using a 23 G needle.  The 
same process was repeated for the other femur and tibias after which the cell 
suspension was spun down at 10,000 rpm for 3 minutes.  The pellet was washed 
with 1X PBS and re-centrifuged.  To lyse red blood cells, red cell lysis buffer was 
added to the pellet and incubated at 370 C for 5 mins.  Cells were centrifuged and 
washed with 1X PBS.  The bone marrow cell pellet was resuspended in 1 ml RPMI 
medium supplemented with 30% serum.  Cells were counted and plated at 2X10^5 
cells/0.5ml medium.  Drug was added directly to the cell suspension with 
incubation for 72 hours.  Cell viability was evaluated using  Alamar Blue dye (10% 
dissolved medium) and absorbance of 570 nm and 600 nm was taken after 30 
minutes with the KC Junior microplate reader.           
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Statistical Analysis 
 Statistical analysis was performed using a two-tailed student’s T test; 
groups with p ≤ 0.05 were considered to be significantly different than vehicle 
controls. 
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CHAPTER 3 Results 
 
I. Effects of JG-03-14 on the DNA damage response pathway in MCF-7 
breast tumor cells. 
In previous studies, (Mooberry et al., 2007) the novel substituted pyrrole 
compound, JG-03-14, was shown to inhibit the polymerization of purified tubulin in 
vitro; evidence was also presented that JG-03-14 bound to the colchicine binding 
site on tubulin.  In a separate report utilizing molecular modeling, it was 
determined that JG-03-14 was likely to form a very stable complex with high 
affinity to tubulin, suggesting a promising role for this compound as a 
chemotherapeutic agent (Tripathi et al, 2008).  Studies within our laboratory 
demonstrated that JG-03-14 promoted cell death in both p53 wild-type MCF-7 and 
p53 mutant MDA-MB-231 breast tumor cells; furthermore, JG-03-14 retained 
activity in multi-drug resistant cells (Arthur et al., 2007; Mooberry et al, 2007).   
Although both of the studies cited above supported the concept that JG-03-
14 acts as a microtubule poison, it was important to test and eliminate the 
possibility that JG-03-14 might also act through the induction of DNA damage.  
Since DNA damaging agents generally induce p53 and p21 (Lanni and Jacks, 
1998), Western blotting was performed using antibodies against p53 and p21 after 
exposure of MCF-7 cells to JG-03-14.   Figure 1 shows that 10 Gy of irradiation (a 
positive control) induced p53 at 1h and 2h and p21 at 2h and 4h.  JG-03-14 failed 
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to induce p53 or p21, indicating that there was no DNA damage response to JG-
03-14 in the p53 wild type MCF-7 cells. 
 
II. Effects of JG-03-14 and other microtubule poisons on viability of 
HCT-116 colon cancer cells  
Due to JG-03-14’s ability to cause cytotoxicity in cells expressing the multi-
drug resistant phenotype, we chose to analyze its potential to interfere with growth 
and or cause cell death in colon tumor cells as these cancers are notorious for 
acquiring resistance against drugs such as colchicine, vinblastine, lapatinib and 
mitomycin (Incles et al., 2003; Martin et al., 2008).  We selected p53 wild type 
HCT-116 cells because of the availability of isogenic derivative cells lines where 
p53 or p21 function have been silenced (for future work).  
Sensitivity of HCT-116 colon tumor cells to JG-03-14 was determined using 
the Crystal Violet Assay (Wosikowski et al. 1993).  Cells were treated with the 
compound by continuous exposure for 72 hours prior to fixation and staining.  
Figure 2A indicates that JG-03-14 demonstrated concentration-dependent growth 
inhibition; at concentrations of 250 nM and 500nM, substantial growth inhibition 
was observed compared to the untreated controls.  Treatment with adriamycin at 
100nM was used as a positive control. All subsequent studies were performed 
using JG-03-14 at a concentration of 500 nM.    
For comparative purposes, we also assessed sensitivity of HCT-116 cells to 
two other microtubule poisons, colchicine and taxol. Colchicine causes 
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microtubule disruption, like JG-03-14, while taxol is a microtubule stabilizer. 
Figure 2B shows that after 72 hours of continuous drug treatments, the three 
compounds all reduced viable cell number by approximately equivalent amounts, 
with a reduction of 75% by JG-03-14, 82.5% by colchicine and 67% by taxol.   
 
III. Cell death of HCT-116 cells after exposure to JG-03-14 and other 
microtubule poisons 
The crystal violet studies do not distinguish between the effects of drugs on 
cell growth arrest or viability.  Consequently, we monitored the effects of JG-03-14 
on cell viability over a period of 5 days.  Figure 3A shows a time dependent 
decline in viable cell number when HCT116 cells were treated by continuous 
exposure to JG-03-14 at 500nM, a concentration that we have previously found to 
be effective in promoting breast tumor growth arrest and cell death (Arthur, 2007).  
All the microtubule poisons produced a similar time-dependent decline in viable 
cell number (Figure 3B). 
 
IV. Assessment of apoptosis in HCT-116 cells after treatment with JG-
03-14 and other microtubule poisons 
The possibility that the cell death observed in HCT-116 in a time dependent 
manner might be due to apoptotic events was assessed using 4’,6-diamino-2-
phenylindole (DAPI), a blue fluorescent nucleic acid stain that binds to double 
stranded DNA.   Figure 4 shows the untreated vehicle control with a clearly 
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defined intact nucleus; in contrast, our positive control, treatment with 10 µM taxol, 
shows nuclear fragmentation characteristic of apoptosis.  The nuclei of cells 
treated with JG-03-14 treated were intact, similar to the untreated cell and vehicle 
controls; however, nuclei of cells treated with JG-03-14 were significantly 
enlarged. 
Since the positive taxol 10 µM control was not a pharmacologically relevant 
concentration, we also assessed the effects of colchicine (100nM) and taxol 
(100nM) on nuclear integrity.  Dapi staining showed that the majority of nuclei 
were fragmented by both treatments after three days (Figure 4).   
 
V. Cell cycle effects of JG-03-14 and other microtubule poisons on 
HCT-116 tumor cells 
Microtubule poisons generally produce G2/M arrest in tumor cells (Tseng et 
al, 2002).  JG-03-14 also produced a G2 arrest in the p53 wild type MCF-7 cells 
(Arthur et al, 2007). The next series of experiments were designed to evaluate the 
nature of growth arrest by JG-03-14 as well as to verify the absence of apoptosis.  
Figure 5 presents FACS analysis of cells treated with JG-03-14 at various time 
points.  JG-03-14 transiently arrested the p53 wild type HCT-116 tumor cells in the 
G2/M cell phase after the first day of treatment, consistent with its microtubule 
destabilizing abilities.  This G2/M block persisted for 72 hours.  Of particular 
interest was the ability of p53 wild type HCT-116 cells to continue to replicate 
following the G2/M arrest, resulting in a hyperdiploid population.  This effect was 
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observed after the first day of treatment and the hyperdiploid cell population had 
more than doubled after 72 hours, where 21 % of the cells were polyploid.  FACS 
analysis confirmed the absence of cells in a sub G1 population both at 24 and 72 
hours following the incubation with 500 nM JG-03-14, confirming the absence of 
apoptosis in HCT-116 p53 wild type cells.  
We also evaluated the effects of the microtubule destabilizer, colchicine, on 
cell cycle distribution. At a concentration of 100nM, where cell growth is inhibited 
by 90% (Figure 3), approximately half the population arrested in the G1 phase 
and the other half accumulated in G2/M after 24 hours (Figure 5).  This was 
shifted to a 49% G2/M arrest and 4.5% in G1 after 72 hours.  A similar cell cycle 
distribution was observed in cells treated with JG-03-14 after 72 hours, where 63% 
were arrested in G2/M and 4.5% were in G1.  Colchicine also induced polyploidy 
in the HCT-116 cells.  2% of the population were hyperdiploid after 24 hours and 
14.7% was hyperdiploid after 72 hours, coinciding with the characteristic of 
microtubule destabilizers (Morrison and Rieder, 2004).  Approximately 34% of the 
cell population consisted of sub G1 cells after 24 h, indicating that approximately 
one-third of the cells were undergoing apoptosis, a characteristic consistent with 
colchicine treatments in other studies (Bonfoco et al, 1995; Wang et al, 1999).  
This finding is also consistent with the DAPI staining studies shown in Figure 4.  
In contrast to the effects of the microtubule destabilizing agents, colchicine 
and JG-03-14, the microtubule stabilizing agent, taxol, at 100nM, arrested the cells 
primarily in the G1/S phase. Approximately 42% and 60% of the cells were in G1 
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after 24 and 72 hours, respectively.  A significant fraction of the cell population (20 
%) was in the sub G1 phase after 24 hours, with an increase to 30% after 72 
hours.  Again, the capacity of taxol to generate a sub G1 cell population confirmed 
the presence of apoptosis in HCT-116 cells that was indicated by the DAPI 
studies.  
 
VI. Assesment of mitotic catastrophe in HCT-116 cells after JG-03-14 
treatment 
We concluded that our p53 wild type HCT-116 cells were not succumbing to 
death via apoptosis after treatment with JG-03-14, based on our Dapi staining and 
FACS analysis.  Due to the presence of enlarged cells and a hyperdiploid cell 
population we considered the possibility of mitotic catastrophe being the mode of 
cell death in HCT-116 tumor cells.  However, Figure 4 failed to demonstrate bi-
nucleated cells and micronuclei that are characteristics of mitotic death 
(DeMasters et al, 2006).    
 
 VII. Induction of autophagy by JG-03-14 in colon cancer cells. 
In our previous work, the p53 wild type MCF-7 and p53 mutant MDA-MB-
231 breast tumor cells demonstrated essentially similar sensitivity to JG-03-14; 
however, their response was different with regard to the modes of cell death. 
MCF-7 cells were not dying through apoptosis based on the FACS analysis and 
TUNEL assay, but rather through autophagy.  MDA-MB231 cells demonstrated 
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both apoptosis and autophagy.  Since the MDA-MB231 cells are p53 mutant 
cancer cells, both apoptotic death and autophagy can be independent of the p53 
pathway.    
Our studies suggested that the death of the  p53 wild type HCT-116 colon 
cancer cells was not triggered through apoptosis after treatment with JG-03-14 
based on the DAPI staining and FACS analysis.  The lack of micronuclei and 
binucleated cells in Figure 4 also ruled out the possibility of mitotic death.  Since 
JG-03-14 was shown in our previous work to promote autophagy in both MCF-7 
and MDA-MB231 breast tumor cells, we also assessed this possibility in the HCT-
116 colon carcinoma cells using acridine orange staining.  Figure 6 shows that the 
untreated control had a uni-vesicular stain that was situated near the nucleus. In 
dramatic contrast, the cells treated with JG-03-14 exhibited a more punctuate 
staining that was distributed throughout the cytoplasm.  The cells treated with JG-
03-14 were also quite enlarged, nearly double the size of the untreated cells, likely 
due to the increased DNA content.   
We also evaluated the capacity of the microtubule poisons, colchicine and 
taxol, to promote autophagy, Figure 7. Surprisingly, a similar pattern of 
punctuated stained vacuoles were also exhibited in cells treated with colchicine 
and taxol, both at 100 nM concentrations.  This was not expected due to the large 
apoptotic population observed by FACS analysis and the fragmented nuclei 
evident with DAPI staining.  
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 VIII. Confirmation of the induction of autophagy by JG-03-14  
To confirm the promotion of autophagy, we used an additional approach, 
staining of autophagic vesicles with monodansylcadaverine.  This is a selective 
stain that binds to the lipid membrane of the autophagosomes, and which would 
be more sensitive to the presence of autophagosomes, unlike the acridine orange, 
which primarily detects the acidic pH of the autophagic vacuoles (Niemann et al., 
2000; Biederbick et al., 1995).  Figure 8 compares the cells treated with JG-03-14 
and controls. After day 3, a substantial amount of monodansylcadaverine staining 
of the autophagic vacuoles is evident in the treated cells compared to the control, 
which showed a single stain that was centered on a uni vacuole, similar to what 
was present in the acridine orange stains.  The monodansylcadaverine positive 
stained vacuoles also showed a highly distributed punctuate pattern throughout 
the cytoplasm. The staining with both acridine orange and monodansylcadaverine 
confirmed the presence of autophagosomes in HCT-116 cells treated with 500 nM 
JG-03-14.  The presence of autophagosomes was also detected in cells incubated 
with either 100 nM taxol or colchicine (Figure 7 and 8).        
 
IX. Assessment of LC3-II protein levels in HCT-116 cells tested with 
JG-03-14 
In efforts to further confirm that autophagy may be the mechanism by which 
JG-03-14 is inducing cell death, we performed western blotting to detect 
conversion of LC3-I to LC3-II at various time points. LC3-I conversion to LC3-II is 
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required for autophagosome maturation and is found both inside and outside the 
vesicle (Amer et al, 2005). We attempted multiple times using both other tumor cell 
lines and cells transfected with GFP-LC3-II via lipofection and nucleofection but 
failed to obtain a clear and reproducible western blot with LC3-II.  Our blots 
showed stains that were just background noise, irrelevant to our interest.  We tried 
using three different antibodies from three different companies that also failed to 
produce anything close to clean blots (data not included). 
  
X. Detection of LC3-II punctate in HCT-116 cells with JG-03-14 
treatments 
LC3-II is a cleaved product of LC3-I and is involved in the formation of 
autophagosomes (Kabeya et al, 2000).  We attempted to confirm that autophagy 
was occurring by detecting the presence of LC-3 II in the treated cells.  HCT-116 
colon tumor cells were transfected with a GFP-LC3 vector via nucleofection and 
the cells were observed under immunofluorescence after 72 hours with 500 nM 
JG-03-14.  After 72 hours of drug treatment, the transfected cells showed a 
punctuate distribution of LC-3 II proteins in the cytoplasm (Figure 9) whereas cells 
transfected with the empty vector lacked any punctuated stains.  Due to the low 
efficiency of transfection and the relatively short life of the GFP fluorescent dye, 
there were very few cells remaining which exhibited the fluorescence after 72 
hours.  
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 XI. Effects of autophagic inhibitors on the response to JG-03-14 
treatment in HCT-116 cells 
There is continuing controversy in the literature as to whether autophagy is 
a cytoprotective mechanism or an actual mode of cell death(Mori et al, 2007; Boya 
et al, 2005).  In a further attempt to confirm the mode of cell death caused by JG-
03-14 and to elucidate the ambiguous role of autophagy, we sought to block 
autophagy.  In efforts to address this question, cells were treated with 3-
methyladenine (3-MA), which has been shown to inhibit autophagy (Seglen and 
Gordon, 1982).  HCT-116 cells were incubated with both 25mM 3-MA and 500 nM 
JG-03-14, after which cells were stained with acridine orange at the various time 
points.  Our untreated controls exhibited one acidic vesicle situated near the 
nucleus as shown in Figure 10.  Cells exposed to JG-03-14 showed distributed 
acidic vesicles that were throughout the cytoplasm.  3-MA however, did not inhibit 
or decrease the generation of acidic vesicles by JG-03-14.  Cells were still 
enlarged and highly punctuated with autophagosomes (Figure 10). There was no 
noticeable difference evident between cells treated with JG-03-14 alone and those 
that were co-treated with 3-MA, suggesting that it was necessary to identify an 
alternative means to interfere with autophagy.  
Bafilomycin A-1 is a macrolide antibiotic that was shown to inhibit 
autophagy at high concentrations (Shacka et al., 2006).  Using the MTT assay, 
contradictory results were obtained in terms of the cytotoxicity of bafilomycin-
A1(data not shown).   Due to the conflicting results of the experiments using the 
38 
MTT assay, we reverted to using the crystal violet assay to test for sensitivity.  
Using this assay, Bafilomycin-A1 at 100 nM did not show any growth inhibition.  
When cells were treated with Bafilomycin-A1 in combination with JG-03-14 at 500 
nM, there was no reduction in the cytotoxic effects of JG-03-14 (Figure 11A). We 
then went on to test the inhibitory effect of Bafilomycin-A1 on autophagy.  Cells 
were co-incubated with JG-03-14 (500nM) and Bafilomycin-A1 (100 nM) with 
continuous exposure prior to acridine orange staining.  Figure 11B showed that 
there was no difference in the extent of autophagy with JG-03-14 alone and with 
JG-03-14 combined with the autophagy inhibitor, Bafilomycin-A1 (Figure 8). 
 
 XII. Effects of JG-03-14 on the DNA damage stress response activation 
pathway in HCT-116 cells 
Although we appear to have ruled out activation of the DNA damage 
response pathway by JG-03-14 in the MCF-7 cell studies (Figure 1) it remained 
possible that JG-03-14 might be activating this pathway in the HCT-116 cells. To 
examine this possibility western blotting was performed at 4 and 8 hours to detect 
levels of p53 and p21.  Figure 12 indicates that JG-03-14 alone did not induce p53 
at 4 and 8 hours similar to the untreated controls.  However, the treatment with 
taxol or colchicine showed induction of p53 or  p21 at 4 and 8 hours.  Irradiation at 
10 Gy was also used as a positive control.  
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 XIII.  Evaluation of the impact of JG-03-14 on bone marrow toxicity 
Bone marrow toxicity is a major concern with cancer chemotherapy.  In 
order for JG-03-14 to be clinically successful, it should not express this mode of 
toxicity.  Figure 13 showed the effects of JG-03-14 on hematopoietic cell viability 
using Alamar Blue staining.  JG-03-14 showed no suppression of bone marrow 
cell growth while taxol and adriamycin produced small effects.   
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Lanes            1        2       3        4        5        6        7        8        9 
 
 
 
Figure 1- Lack of induction of p53 and p21 by JG-03-14 in MCF-7 breast tumor cells. 
MCF-7 cells were incubated with JG-03-14 (500nM) for the time periods indicated before 
harvesting and subjecting cell lysates to western blotting.  Irradiation (10 Gy) was used as 
a positive control and beta actin was the loading control.  p53 and p21 were induced by 
irradiation (lanes 4, 7, and 9).   
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Figure 2 –  Drug sensitivity of HCT-116 colon carcinoma cells by the Crystal Violet 
assay. A. Sensitivity to JG-03-14. B.  Sensitivity  to other microtubule poisons. Cells were 
seeded in a 48-well plates and incubated with the indicated compounds at the various 
concentration for 72 h.  DMSO was a negative control and Adriamycin was used as a 
positive control.  Values shown represent means ± standard errors for three replicate 
experiments.  Growth inhibition at 250 nM and 500 nM JG-03-14 was statistically 
significant compared to vehicle controls with p ≤ 0.05 for HCT-116 cells.   
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Figure 3 – Growth arrest and cell death in HCT-116 cells. Cell death was evaluated in 
response to a continuous 5 day exposure to 500 nM JG-03-14, 100nM colchicine or 100nM 
taxol.  Cell viability was monitored using trypan blue exclusion. Studies were independent 
of each other.  A. Time course response of HCT-116 cells to JG-03-14.  Adriamycin (100 
nM )was used as our positive control (not shown).  B.  Time course response of HCT-116 
cells to JG-03-14 500nM, colchicines 100nM and taxol 100nM. Values shown represent 
means ± standard errors for three replicate experiments.  
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Figure 4– Assessment of effects of JG-03-14 on nuclear integrity of HCT-116 cells.   
HCT-116 cells were treated with the various drugs by continuous exposure.  After 72 h, 
slides were prepared with adherent and non-adherent cells, fixed, and stained.  Cells treated 
with JG-03-14 showed very minimal nuclear perturbations compared to the pronounced 
nuclear fragmentation evident in treatments with taxol and colchicine.      
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Figure  5- Influence of JG-03-14 on cell cycle progression of HCT-116 cells. Cell cycle 
distribution was determined by flow cytometry of HCT-116 cells exposed to the various 
microtubule compounds.  Cells were exposed for 72 h, at which time were harvested and 
stained with propidium iodide staining (PIF) solution.  Flow cytometry PIF voltages were 
altered for the treatment groups compared to the control to accommodate the increasing 
polyploidy observed following drug treatment at 24h and 72 h.   
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Figure 6- Determination of autophagy by acridine orange staining.  HCT-116 cells were 
incubated with JG-03-14 at 500 nM for 3 days, stained, washed, and observed by 
fluorescence microscopy.  Green stain reflects the background while bright orange staining 
occurs in acidic (autophagic) vacuoles.  Although the control showed one acidic vacuole , 
it was localized to the nucleus and is different from the accumulation of the distributed 
autophagic vacuoles seen in treatment with JG-03-14.  All photos are taken at 20X. 
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Figure 7 -  Comparing autophagy by microtubule poisons in HCT-116 cells using acridine 
orange staining.  HCT-116 cells were incubated with the different treatments for 3 days, 
stained, washed, and observed by fluorescence microscopy.  These photos were taken 
without the green background which better differentiates the staining.  Bright orange 
staining occurs in acidic (autophagic) vacuoles.  Although the control showed one acidic 
stained vacuole, it was localized to the nucleus and is different from the accumulation of 
the distributed autophagic vacuoles seen in our treatment with JG-03-14.  All photos were 
taken at 20X.   
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Figure 8– Determination of autophagic vacuole formation using monodansylcadaverine 
(MDC) staining.  HCT-116 cells were incubated with the different microtubule poisons for 
3 days, stained, washed, and observed by flurescence microscopy.  Bright blue staining 
occurs in the autophagic membrane Thapsigargin 0.5 uM was used as our positive control.  
All photos were taken at 20X.   
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Figure 9– Detection of the LC3-II protein in cells treated with JG-03-14.  HCT-116 cells 
were transfected with (A) GFP (B) empty-GFP vector (C) GFP-LC3-II vector and treated 
the following day with JG-03-14 (500 nM, continuous exposure for 72 h).  Photos were 
taken at 10 X for (A)-(C) and 40X for (D).   
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Figure 10–Effects of the autophagy inhibitor, 3-methyladenine (3-MA) on the response of 
HCT-116 cells to JG-03-14.  HCT-116 cells were co-incubated with JG-03-14 (500 nM) 
and 3-MA (25 mM) by continuous exposure for 3 and 5 days, stained with acridine orange, 
washed, and observed by fluorescence microscopy.  Acidic stained vacuoles were still 
present even after day 5.  All photos were taken at 20X  
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
A. 
CRYSTAL VIOLET HCT-116 p53 wild type 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
UNTX DMSO JG 500nM Baf 100nM Baf100JG500
TREATMENT
A
B
S
O
R
B
A
N
C
E
 
 
B. 
 Control     JG-03-14 500 nM 
   
JG-03-14 500 nM + Bafilomycin-A1 100 nM 
 
 
 
 
 
 
 
 
53 
 
 
Figure 11- (A) Growth inhibition with the combination treatment was assessed using the 
crystal violet assay.  Cells were seeded in a 48-well plates at 20,000 cells per well and 
incubated with the indicated compounds for 72h.  The combination of JG-03-14 500 nM 
and Bafilomycin-A1 100 nM was added for continuous exposure.  DMSO was our 
negative control.  Values shown represent means ± standard errors for three replicate 
experiments.   (B) Treatment of HCT-116 cells using the autophagy inhibitor, 
Bafilomycin-A1.  HCT-116 cells were plated in a 6-well plate and co-incubated with JG-
03-14 (500 nM) and Bafilomycin-A1 (100 nM) continuous exposure for 3 days, stained 
with acridine orange, washed, and observed by fluorescence microscopy.  Acidic stained 
vacuoles were still detected after treatment with Bafilomycin.  All photos were taken at 
20X. 
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Figure 12– Assessment of DNA damage response protein expression in HCT-116 cells.  
HCT-116 cells were treated with either irradiation or the indicated drugs and the 
expression of p53 and p21 was assessed by western blotting at the indicated time points. 
JB=JG-03-14 (500 nM) + Bafilomycin-A1 (100) nM; Tax=taxol (100nM); 
Col=colchicines (100 nM); Un= untreated control; JG=JG-03-14 (500 nM); IR=irradiation 
(10 Gy). 
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Figure 13– Assessment of bone marrow suppression by JG-03-14 in HCT-116 cells.  Bone 
marrow cells were obtained from C57BL6 mice and seeded in a 24-well plates at  
2 x 10^5 cells per well.  Cells were incubated for 72 h with the drug treatments.  Viable 
cell numbers were assessed using the Alamar Blue assay.  DMSO solvent was used as a 
control.     
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CHAPTER 4 Discussion 
 
Colorectal cancer remains the second leading cause of cancer morbidity in 
the US.  There were approximately 98,200 new cases diagnosed with about 
48,100 deaths in 2001 (Greenlee et al, 2001).  Colon cancer is a heterogeneous 
disease which evolves through two pathways: the major genetic pathway is a 
consequence of chromosomal instability and accounts for 70-85% of colon cancer 
cases while the non-genetic pathway, which accounts for 15% of cases, is 
characterized by a loss of DNA mismatch repair system (MMR) and MSI( 
microsatellite instability) (Popat et al, 2005; Jass et al, 2002; Zlobec et al, 2008).  
Surgery is the primary treatment, with radiotherapy given before or after surgery to 
prevent local recurrence(Mainprize et al, 1998).   Although colon cancer can be 
successfully treated with surgery when detected before it has metastasized out of 
the colon, it has been shown that about half of the resected patients develop 
recurrent disease(Sorensen et al, 2008).  Colon cancer is also notoriously 
unresponsive to chemotherapy.  Current chemotherapeutic treatments for 
colorectal cancer involve 5-fluorouracil, monoclonal antibody therapy, and 
inhibitors of EGFR and VEGF (Shia, 2008;Gallegos-Arreola et al, 2008; Zrieki et 
al, 2008; Schwartz RN 2008; Igbal and Lenz, 2004) . However, patient survival is 
generally limited due to the development of drug resistance and metastatic 
disease.   
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The primary reasons that colon cancer is thought to be resistant to most 
conventional chemotherapies includes mutation of p53, constitutive receptor 
activation, Kras overexpression, multidrug resistance pumps, overexpression of 
antiapoptotic molecules in the BcL family, silencing of DNA methylation proteins, 
and constitutive activity of NFkB (Zlobec et al, 2008; Sumitomo et al, 1999; 
Szakacs et al, 2006).   
We have previously found that the substituted pyrrole, JG-03-14, is able to 
promote cell death in both p53 wild type and p53 mutant breast tumor cells 
through both autophagy and apoptosis (Arthur et a, 2007).  Autophagy is the 
primary mode of cell death in the MCF-7 cells while both autophagy and apoptosis 
were observed in the MDA-MB-231 cells.  We reasoned that if one of the reasons 
for colon cancer resistance to therapy is its capacity to evade apoptosis, then a 
drug that promotes autophagy might be effective.   
We performed studies using the HCT-116 colon cancer cell line. One 
reason for choosing this line is that isogenic lines with disruption of p53 and p21 
are available for comparative studies ( although these studies will be performed in 
the future). HCT-116 cells were sensitive to JG-03-14 at 250 nM and 500 nM 
concentrations; at the 500 nM concentration, JG-03-14 demonstrated growth 
inhibition of 75% compared to the untreated control.  This was also the 
concentration that was effective against MCF-7, MCF-7/caspase-3, and MDA-MB-
231 cells in previous studies from this laboratory (Arthur et al, 2007).  The 
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microtubule stabilizer, taxol, and the microtubule destabilizer, colchicine, similarly 
inhibited growth of HCT-116 cells, although at concentrations of 100nM.  
The majority of the population of cells treated with 500 nM JG-03-14 were 
arrested in G2/M, a finding which correlates with the effects of other microtubule 
destabilizers (Azeddine et al., 1998).  HCT-116 cells treated with colchicine also 
arrested in the G2/M phase after day 3 of treatment, a finding that was different 
than the response to taxol in which the population was arrested in the G1 phase.  
This finding suggest that there may be a difference in the way microtubule 
destabilizers such as colchicine and JG-03-14 act on the cell cycle compared to 
the microtubule stabilizer, taxol.  
 It is likely that the difference between the microtubule stabilizer and 
destabilizer is in the way these compounds interact with the spindle assembly 
checkpoint.  The spindle assembly checkpoint is activated in the presence of 
unattached kinetochores or the absence of tension between paired kinetochores 
(Xia et al, 2004).  Since centrioles organize the spindle apparatus that is required 
for chromosome segregation, any defect in it or its kinetochores would activate the 
spindle assembly checkpoint ( Rudner et al, 1996).  It has been observed by Sudo 
et al,  (2004) that taxol, which binds on beta tubulin, stabilizes the microtubules 
and interfere with the dynamics of the spindle apparatus formation and therefore 
activate the spindle assembly checkpoint to arrest the cells at mitosis.  This may 
explain why we observe G1 cell cycle arrest in the HCT-116 cells treated with 
taxol.  On the other hand, the microtubule destabilizers, colchicines and JG-03-14, 
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interfere with the formation of the spindle apparatus and perhaps may abolish the 
formation of the spindle kinetochores completely.  If it is in fact the case, then the 
replicating cells lacking centrioles thus will also lack kinetochores or spindle 
apparatus; without the spindle apparatus the spindle assembly checkpoint will not 
be activated.  Thus, the cells treated with JG-03-14 and colchicine which 
presumably lack a spindle assembly checkpoint to promote arrest in G1 instead 
undergo mitotic slippage and continue to re-replicate without division.  However, it 
is more likely that the formation of the spindle apparatus may occur before the 
microtubule depolymerizers JG-03-14 and colchicine take a complete toll on 
breaking down all microtubule structures (centrioles, spindles, kinetochores); 
consequently, in the case of colchicines we observe a population of cell arrested in 
G1 (24.79 %) and in G2 (44.28%).  Since the mitotic block triggered by the spindle 
assembly checkpoint is not permanent, cells can undergo mitotic slippage and re-
replicate, a reason why we see the population of cells treated with colchicine and 
JG-03-14 in the G2 cell cycle arrest after the first 24 hours (Weaver et al, 2005).  
Once the depolymerizing agents continue to destroy the integrity of the 
microtubules, the spindle assembly becomes dysfunctional; hence the cell will lack 
a spindle assembly checkpoint to halt the cell cycle progression and will continue 
to re-replicate and become hyperdiploid, as evident after 72 hours with JG-03-14 
or colchicines treatment.  
Normally, activation of p53 is triggered by DNA damage, spindle disruption, 
hypoxia, radiation, or chemotherapeutics(Das et al, 2001;Amundson et al, 1998; 
60 
Lowe 1999)  Although JG-03-14 treated cells failed to demonstrate induction of 
either p53 or p21, this finding is different from other studies using microtubule 
poisons showing activation of p53 and p21.  When p53 is induced, this generally 
arrests the cells in the G1 phase of the cell cycle by activating the cdk2-cyclin-B 
inhibitor p21/WAF1/Cip1; p53 can also activate the DNA damage repair response 
if there is any DNA damage that requires repair before the cell can resume the 
normal cell cycle.  In cases where DNA damage is beyond repair, p53 may 
activate the apoptotic pathway(Barboule et al, 1997; De Leonardo et al, 1997; 
Khan et al, 1998).  This checkpoint pathway was found to function in colchicine 
and taxol studies showing the induction of p53 and p21 that eventually lead to 
apoptosis, which is similar to our finding(Tao et al, 2005; Taylor et al, 
1997;Masuda et al, 2003).  Concurrent with the checkpoint activation, taxol at 100 
nM induced a G1/S arrest with a population of cells evident in sub G1 even after 
three days of treatment, indicating that taxol kill cells in part through the apoptotic 
pathway (Wagenknecht et al., 1998; Blajeski et al., 2001).  JG-03-14 failed to 
arrest cells in a G1, which correlated with a lack of induction of p53 and p21 in our 
studies.   
Although there was no indication of a DNA damage response to JG-03-14, 
we sought to determine if cell death might be occurring through checkpoint 
independent apoptosis (Shi et al, 2008).  However, Dapi staining showed that JG-
03-14 treatment did not cause DNA fragmentation that would be indicative of 
apoptosis (Notterman, et al, 1998).  The difference in the induction of p53 and p21 
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and the large population of sub G1 cells found after colchicine treatment compared 
to the relatively small population and the lack of p53 and p21 induction by JG-03-
14 raised the question of how microtubule depolymerizing agents that bind to the 
same site on tubulin may activate different signaling cascades and different cell 
death pathway.  
 With reference to the previous discussion on spindle assembly checkpoint, 
the study by Chan et al, (2008) demonstrated that the functional spindle assembly 
checkpoint and p53 are required for the postmitotic G1 checkpoint.  Consequently, 
in order for the spindle assembly checkpoint to be activated, the cells must be 
actively replicating with a functional spindle assembly.  In regards to the kinetics of 
microtubule assembly, microtubules grow toward the (+) end of the beta tubulin, in 
which tubulin-GTP addition is coupled directly to the hydrolysis of a longitudinally 
adjacent tubulin-GTP also known as the Lateral Cap Model (Vandecandelaere et 
al, 1999).  The microtubules will grow with the addition of one tubulin-GTP and will 
shrink at the rate of hydrolysis of one tubulin-GTP at a steady state; the affinity of 
tubulin-GTP for a site at the end of the microtubule is highest when tubulin-GTP 
content at the site is high The polymerization of tubulin-GTP to the (+) beta end is 
found to stabilize the microtubule structure, where lack of such structure would 
make the ends unstable and rapidly depolymerize whereas the (-) alpha end tends 
to be stable when exposed and would resume polymerization (Desai et al, 1997).  
In addition, microtubule associated proteins (MAP) are found to act with tubulin on 
the alpha and beta interface to stabilize the microtubules and phosphorylation of 
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MAPs can lead to increased microtubule turnover (Rodionov et al, 1990; McNally 
1996).  Now, recall that colchicine binds on the beta tubulin where it prevents beta 
(+) tubulin-GTP from being polymerize, or added to the microtubule whereas; JG-
03-14 binds on the alpha and beta interface of tubulin (Jayanarayan et al, 2002).  
Due to this binding, JG-03-14 may have a more profound impact on the rate at 
which microtubules depolymerize because: (1) by binding to the alpha and beta 
interface, it can block the polymerization of tubulin at the (+) beta end as well as 
prevent the (-) alpha end from resuming polymerization and (2) it could lead to 
displacement of MAPs and enhance the turnover rate of microtubules.  This rapid 
turnover of microtubules induced by JG-03-14 may explain why the treated cells 
failed to exhibit any cell cycle arrest in the premitotic G1 phase and a lack of p53 
activation because (1) the cell cycle arrest in premitotic G1 requires the activation 
of the spindle assembly checkpoint; (2) since JG-03-14 may bind on a site that 
would enhance rapid turnover of microtubules, there would be no spindle 
formation to activate the spindle assembly checkpoint; and (3) since both the 
functional spindle assembly checkpoint and p53 are required for the postmitotic 
G1 checkpoint, this may explain why we did not see induction of p53 in HCT-116 
tumor cells.  However, further work is required to ascertain whether these 
hypothesis can be validated.      
We observed a hyperdiploid population after treatment with JG-03-14 and 
colchicine, due to the ability of cancer cells to undergo mitotic slippage out of the 
G2/M arrest and re-replicate their DNA (Gross et al., 1995).    This process 
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involves DNA replication without cell division where 4N cells re-replicate to form 
8N and is called endoreduplication.  However, this condition, which promotes 
polyploidy, where cells continue to synthesize DNA but fail to undergo cytokinesis, 
is thought to exist primarily in cells lacking a functional p53; where p53 is 
functional,  the DNA damage response acts to arrest cells in G1 post-mitotic 
slippage (Stewart et al., 1999; Elhajouji et al, 1998).  Studies which indicate that 
p53 is required to prevent DNA reduplication are not consistent withour findings 
(Aylon et al., 2006).  In fact, our previous studies showed that MDA-MB-231 
mutant p53 breast tumor cells, but not p53 wild type MCF-7 cells, undergo 
endoreduplication(Arthur et al, 2007).  The ability of the wild type p53 HCT-116 
colon cancer cells to undergo mitotic slippage indicates that tumor cells can 
become polyploid independent of functional wild type p53.  By inducing a rapidly 
activated cell death  response that is independent of functional p53 (and 
presumably p21) JG-03-14 may therefore bypass the common classical pathway 
of acquired resistance to antineoplastic drugs through loss of checkpoint function.  
However, the role of functional p53 and p21 in JG-03-14 action remains to be fully 
elucidated with studies using HCT-116 cells where p53 or p21 are silenced.   
Another question that arises is the basis for the difference in the mode of 
cell death between microtubule destabilizers JG-03-14 and colchicine in HCT-116 
cancer cells.  Studies have shown that although cancer cells can undergo mitotic 
slippage and become hyperdiploid, this tetraploidy is still regulated by p53, and 
that p53 can eventually arrest and abort the polyploidy cells through apoptosis. 
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This was confirmed from our cell cycle analysis and the induction of p53 and p21 
upon colchicine treatment (Cross et al., 1995; Vogel et al, 2004).  However, this 
was not evident in cells treated with JG-03-14, suggesting that there may be a 
delayed apoptosis since we did see a small population of sub G1 cells.  
Alternatively, the cells may die through autophagy. 
Autophagy is a process that involves the formation of double membrane 
acidic vesicles, the autophagosomes, which fuse with lysosoms to complete 
protein degradation.  In acridine orange-stained cells, the cytoplasm and nucleus 
fluoresce bright green and dim red respectively, whereas the acidic compartments 
fluoresces bright red during autophagy (Paglin et al., 2001).  Our observations of 
autophagic vacuoles stained using acridine orange in JG-03-14 treated cells 
indicates the presence of autophagosomes.  The untreated control is also stained  
with acridine orange; however, there is only one acidic compartment per control 
cell, situated near the nucleus.  Similar to the treatment with JG-03-14, taxol and 
colchicine also caused distributed acridine orange stained autophagic vacuoles 
throughout the cytoplasm.  The literature does indicate that in some cases  
autophagy is an alternative mode of cell death when apoptosis is defective due to 
p53 mutation or its inhibition (Kim et al., 2006; Yu et al., 2006).  Since our cells are 
not p53 deficient, this explanation would not apply.  However, other work has 
shown that autophagy may contribute to the tumor suppression function of p53, ( 
Jin 2005; Zeng et al., 2007).  There was also a suggestion that p53 may be 
involved in the induction of autophagy (Abida et al, 2008).   
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The positive monodansylcadaverine stain confirms the presence of 
autophagosomes; this is a more reliable stain for autophagic vacuole because of 
its interaction with the autophagic membrane and not just the acidic compartment 
of the autophagosome (Biederbick et al., 1995).   
It appears that cell death in HCT-116 cells treated with JG-03-14 is due to 
induction of autophagy, as there was only a very small population of sub G1 cells 
that would suggest the occurrence of apoptosis.  We also failed to detect evidence 
of mitotic catastrophe, although this mode of cell death would be consistent with 
cell enlargement.  Although we do not know the exact mechanism of autophagic 
death induced by JG-03-14, the literature suggests that it could be a consequence 
of selective protein degradation, specifically catalase degradation causing an 
accumulation of ROS or degradation of other essential proteins that would 
eventually kill the cells (Yu et al., 2006; Onodera and Ohsumi, 2004).  Future 
studies using reactive oxygen species (ROS) inhibitors and measurement of 
catalase could help to clarify this question. 
Drugs that have been used in suppressing autophagy include 3-
methyladenine(3-MA), bafilomycin-A1, and chloroquine (Shacka et al, 2006; Boya 
et al., 2005).  Phosphatidylinositol 3-kinase (PI3K) is shown to be involved in the 
autophagic pathway in tumor cells but has only been shown to be activated 
through growth factor or amino acids (Blume-Jensen and Hunter, 2001; Vivanco 
and Sawyer, 2002).  3-MA acts through inhibition of the PI3K pathway to inhibit 
autophagy only during nutrient depletion but may not be a specific inhibitor for JG-
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03-14 induction of autophagic death, since the autophagy promoted by JG-03-14 
is not due to nutrient deprivation that would otherwise be activated by PI3K-Akt-
mTor (Reggiori and Klionsky, 2002).   Attempts to use 3-MA for inhibition  were 
unsuccessful, as acidic stained vacuoles were still present when cells were co-
incubated with JG-03-14 at 500 nM.  The persistent cell death observed may be 
due to the failure of 3-MA to inhibit autophagy.      
We also attempted to inhibit autophagy using Bafilomycin-A1, a vacuole 
ATP-ase inhibitor that interferes with the pH of lysosomes.  Bafilomycin-A1 is 
shown to prevent the fusion of lysosomes to autophagosomes, thereby inhibiting 
completion of autophagy (Yamamoto et al, 1998).  Cells treated with Bafilomycin-
A1 at 100 nM and JG-03-14 500 nM were enlarged and showed acridine orange 
staining similar to the JG-03-14 treated cells, with continued cell death.   
If autophagy is inhibited by Bafilomycin-A1 with JG-03-14 treatment, why do we 
continue to see the acidic stains and cell death?  Bafilomycin-A1 has the 
demonstrated ability to induce accumulation of autophagic vacuoles concomitant 
with apoptotic death at concentrations exceeding 10 nM (Boya et al., 2005).  With 
100 nM Bafilomycin-A1 treatment in combination with JG-03-14, Dapi staining 
showed an abundance of nuclear damage that was not detected with JG-03-14 
treatment alone.  This could indicate that the co-incubation induced an alternate 
mechanism of cytotoxicity and cell death, specifically apoptosis; however we 
would need to assess nuclear fragmentation to clarify this question.  
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Since Bafilomycin-A1 acts at the level of interfering with fusion and not 
down regulation of the autophagosome formation, this may be a reason why 
autophagosomes are detected after this treatment (Shacka et al., 2006).  When 
autophagosomes sequester protein for degradation, they may selectively 
sequester essential proteins.  When this occurs, and autophagy is inhibited by 
Bafilomycin A-1, the cells can revert to another mode of death.     
LC3-II is a proteolytic product of LC3-I protein that is required for the 
formation of autophagosomes and is a known marker of autophagy.  Before the 
induction of autophagy, GFP-LC3 shows a diffuse localization of green within the 
cytoplasm; once autophagy is induced, GFP-LC3 will appear as a punctuated dot 
that is distributed in the cytoplasm (Zeng et al., 2007).  Our GFP-LC3-II punctuate 
pattern within the cytoplasm is consistent with autophagic activity after incubation 
with JG-03-14 500 nM.  Unfortunately, since we failed to include an untreated 
control(Niemann et al., 2000),  this assay is not fully confirmatory of autophagy. 
In summary, our studies lead to a number of conclusions.  Although the 
response to JG-03-14 was found to occur at a higher concentration than colchicine 
and taxol, JG-03-14 did not show bone marrow toxicity and thus may have a 
higher therapeutic index compared to the other two agents.  Colchicine is not used 
in the clinic because it has been shown to be a substrate for the p-glycoprotein 
MDR pump as well as the glutathione S-transferase found in resistant cells (Ruiz-
Gomez et al, 2000).  Colchicine has also been shown to suppress bone marrow 
function (Liu et al, 2008; Harris et al, 2000).  
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Different microtubule targeting agents can cause either a G1 or G2 arrest, 
and the arrest may be p53-dependent or p53 independent.  The fact that JG-03-14 
induced a G2 arrest and there was no induction of p53 indicates that JG-03-14 is 
acting through a p53 independent mechanism.  This is significant in that cancers 
that acquire resistance via evasion of the p53-dependent mechanism may be 
sensitive to the alternative mechanism of cell cycle arrest which could ultimately 
lead to an alternative death signal.  Since adjuvant radiotherapy is often used in 
preventing colon cancer recurrence, a G2/M block induced by JG-03-14 could also 
stage the colon cancer cells for radio sensitization (Jorgensen et al, 2007). 
The results presented above have potentially important implications for JG-
03-14 as a clinically effective agent due to its ability to promote autophagy in colon 
cancer cells.  By targeting autophagic induction of tumor regression, JG-03-14 
may be able to bypass colon cancer’s high metastatic rate and resistance to 
apoptosis; furthermore, JG-03-14 is not a substrate for the multidrug resistant 
pump.   
Drugs that target microtubules are among the most effective in treating 
childhood and adult tumors.  Though drugs such as combretastatin A-4 and 2ME2 
bind to the same site on tubulin, they have different effects on tumor vasculature.  
2ME2 has anti-angiogenic actions while combretastatin A-4 has antivascular 
activities that lead to a rapid collapse in tumor vasculature (Mooberry et al, 2003, 
Griggs et al, 2001).  The ability of JG to bind to tubulin and its action as a 
destabilizer generated interest in its potential effect on tumor vasculature.   
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Angiogenesis begins with the recruitment of angioblasts and other extracellular 
matrix proteins.  Subsequently, maturation into endothelial cells is crucial for 
vascular tubule formation (Tozer et al, 1999).  Unpublished studies by our 
collaborator, Dr. Edward Schwartz, showed that JG-03-14 at 100 nM was able to 
inhibit endothelial cell tube formation, attachment, and migration, which indicates 
that JG-03-14 may have potential as a chemotherapeutic drug for cancer. 
Another reason why JG-03-14 has potential as a chemotherapeutic is that it 
may not induce bone marrow toxicity.  Bone marrow toxicity has been an issue 
with many chemotherapeutics such as colchicine and taxol, which limits their use 
in cancer treatment (Liu et al, 2008; Cardinali et al, 1961).   
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